Aug 29, 2002
Brian, in your comment re Sustivia/Lypo, you mentioned that all NRTIs are responsible for Lypo- 3tc being the least. Having said that, is it better to be on PIs? Simply put, where does the medical/science community stand with regards to this phenomenon- lypoatrophy and lypodystrophy? Youre a very compassionate manthanks again,
| Response from Dr. Boyle
Tough to say. There are some data that indicate that PIs without nucleoside analogues (NAs) are associated with a relatively low rate of lipodystrophy, and there's some data that show the converse to be true, i.e., that NAs without PIs have a relatively low rate of lipodystrophy. There is also data to suggest that the lower your T cells are when you start therapy that the more likely you are to get lipodystrophy; however, lipodystrophy has also been associated with time on ARV therapy. So, it's a difficult decision regarding when and what to start to minimize the risk of developing lipodystrophy. My own belief is that you should start ARV therapy with reasonable T cells (closer to 350 than 200) and with regimens that are relatively unlikely to cause lipodystrophy (non-nucleoside HAART regimens seem best), and then watch for it and take action if it starts to develop (since once it becomes advanced it is very difficult to reverse).
Get Email Notifications When This Forum Updates or Subscribe With RSS
This forum is designed for educational purposes only, and experts are not rendering medical, mental health, legal or other professional advice or services. If you have or suspect you may have a medical, mental health, legal or other problem that requires advice, consult your own caregiver, attorney or other qualified professional.
Experts appearing on this page are independent and are solely responsible for editing and fact-checking their material. Neither TheBody.com nor any advertiser is the publisher or speaker of posted visitors' questions or the experts' material.